Navigating GLP-1 Side Effects: A Practical Guide for Patients
A comprehensive guide to managing the common gastrointestinal side effects of GLP-1 medications and strategies to preserve lean muscle mass during treatment.
A comprehensive guide to managing the common gastrointestinal side effects of GLP-1 medications and strategies to preserve lean muscle mass during treatment.
Recent studies reveal that GLP-1 receptor agonists offer significant cardiovascular protection independent of weight loss, shifting the paradigm in preventative cardiology.
Exploring the paradigm shift of GLP-1 receptor agonists from weight loss and diabetes management to potent cardiovascular risk reduction based on landmark clinical trials.
Reports of stomach paralysis linked to semaglutide and tirzepatide are rising. Here is what the published evidence actually shows, who is at higher risk, and what proper monitoring looks like.
Eli Lilly's orforglipron, Novo's next-gen oral semaglutide, and Pfizer's danuglipron exit represent the most consequential pipeline shift in metabolic medicine. Here is the evidence as it stands in 2026.
A clinical comparison of semaglutide and tirzepatide based on SURMOUNT-5, STEP, and SURPASS data — efficacy, tolerability, and what the receptor pharmacology tells us about who responds best.
From the Diary of a CEO spotlight to published trial data: what retatrutide is, what it may do for the body, and how to access physician-led care safely.
Board-certified physicians, quarterly labs, muscle-preserving protocols, supplement Rx, and resistance training guidance — all included.
See the Program →